All News

Findings from a phase 2 study demonstrate the feasibility of conducting genomically driven trials among patients with meningiomas.

Ifeoma Dikeocha, PhD, explains why triple-negative breast cancer is uniquely sensitive to fasting mimicking diets.

Deb Schrag, MD, MPH, will assume the role as ASCO president in 2027, and hopes to continue the work of transcending global, political, and geographic barriers in oncology.

While institutional cancer centers boast large amounts of resources, community centers do not always have the resources to initiate clinical trials, according to Loretta Nastoupil, MD.

A PDUFA data of the second quarter of 2026 has been set for Dato-DXd in patients with unresectable or metastatic TNBC.

A phase 1/2 trial will evaluate N17350 in patients with pretreated, advanced solid tumors, such as head and neck neoplasms, NSCLC, and melanoma, among others.

Phase 1 QUILT-3.002 data showed that combining an IL-15 superagonist with rituximab achieved a 78% CR rate in those with rituximab-refractory disease.

No differences in complication rate were observed between the MIXREAL and control groups among those treated for kidney cancer in the REALITATEM trial.

Infusing chemoimmunotherapy earlier in the day also correlated with improvements in responses among patients with NSCLC in a phase 3 trial.

A biologics license application is planned to be sent to the FDA for OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma.

Potential FDA approval of teclistamab plus daratumumab may offer another option in the multiple myeloma armamentarium, said Surbhi Sidana, MD.

The consolidation of oncologists and the transition to bispecific antibodies and CAR T-cell therapies are among factors that have led to increasing cancer care costs.

Treatment with zanzalintinib plus atezolizumab led to improvements in OS and PFS vs regorafenib alone in patients with metastatic colorectal cancer.

CancerNetwork spoke with Arturo Loaiza-Bonilla, MD, MSEd, FACP, regarding his insights about recent advancements for AI in oncology.

Additional translational research may help inform the design of next-generation therapies for patients with multiple myeloma, said Manoj Bhasin, PhD, MS.

Real-world data presented at the 36th Annual IPCU build upon findings from the phase 3 TITAN trial evaluating apalutamide in this CSPC population.

Rivoceranib plus camrelizumab achieved a median OS of 23.8 months vs 15.2 months with sorafenib alone in patients with unresectable hepatocellular carcinoma.

IFx-2.0 showed a clinical benefit in an early phase 1 trial and has now been given orphan drug designation by the FDA for patients with stage IIB to IV cutaneous melanoma.

In palliative care, AI may serve as a supportive tool rather than a replacement of clinical judgment, said Ram Prakash Thirugnanasambandam, MBBS.

According to investigators of the phase 3 SCOT trial, most patients with colon and rectal cancer should be receiving only 3 months of adjuvant treatment.

Artificial intelligence may be used in CT scans to help detect early-stage disease in at-risk patients undergoing screening for cancer.

Intensive surveillance and surgical resection for hepatic metastases from uveal melanoma improved long-term remission in a retrospective study.

Kathie-Ann Joseph, MD, MPH, FACS, explored evolving surgical strategies for inflammatory breast cancer and phyllodes tumors.

One of the lesser-known costs of undergoing cancer treatment is the loss of work opportunities, according to Loretta Nastoupil, MD.

Soumen Das, MBBS, MS, FACS, details how the BC-RADS-2 study standardizes clinical breast examinations to combat diagnostic delays and improve early-stage detection in low-resource oncology settings.

Pembrolizumab administered before surgery in patients with desmoplastic melanoma led to high pathologic complete response rates in the SWOG S1512 trial.

Soumen Das, MS, FACS, discusses the BCRADS-2 study, a validated clinical scoring system designed to standardize breast cancer triage and downstage palpable lesions in low- and middle-income countries.

An unadjusted indirect comparison analysis of the SEQUOIA and AMPLIFY trials revealed improved PFS with zanubrutinib vs acalabrutinib plus venetoclax.

The median progression-free survival was significantly higher with donor vs placebo fecal microbiota transplantation in this RCC population.

In the phase 1/2 ReFocus trial, lirafugratinib demonstrated a median PFS of 11.3 months in the chemotherapy pretreated, FGR inhibitor-naïve CCA population.